95 related articles for article (PubMed ID: 10086751)
1. Behavior therapy for urge incontinence in older women.
Velez JB
J Fam Pract; 1999 Mar; 48(3):168-9. PubMed ID: 10086751
[No Abstract] [Full Text] [Related]
2. Global ratings of patient satisfaction and perceptions of improvement with treatment for urinary incontinence: validation of three global patient ratings.
Burgio KL; Goode PS; Richter HE; Locher JL; Roth DL
Neurourol Urodyn; 2006; 25(5):411-7. PubMed ID: 16652380
[TBL] [Abstract][Full Text] [Related]
3. Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study.
Urinary Incontinence Treatment Network (UITN)
Contemp Clin Trials; 2007 Jan; 28(1):48-58. PubMed ID: 16919506
[TBL] [Abstract][Full Text] [Related]
4. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
5. "Unblinding" in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident.
DuBeau CE; Khullar V; Versi E
Neurourol Urodyn; 2005; 24(1):13-20. PubMed ID: 15570576
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of female urinary incontinence: an overview].
Palomba S; Falbo A; Damiano R; Zullo F
Minerva Ginecol; 2007 Oct; 59(5):543-8. PubMed ID: 17912180
[TBL] [Abstract][Full Text] [Related]
7. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Wein AJ
J Urol; 2005 Jun; 173(6):2056-7. PubMed ID: 15879827
[No Abstract] [Full Text] [Related]
8. Behavioral and drug therapy for urinary incontinence.
Goode PS
Urology; 2004 Mar; 63(3 Suppl 1):58-64. PubMed ID: 15013654
[TBL] [Abstract][Full Text] [Related]
9. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride.
Grüneberger A
Br J Obstet Gynaecol; 1984 Mar; 91(3):275-8. PubMed ID: 6367811
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of pelvic floor muscle exercise therapy supplemented with a health education program to promote long-term adherence among women with urinary incontinence.
Alewijnse D; Metsemakers JF; Mesters IE; van den Borne B
Neurourol Urodyn; 2003; 22(4):284-95. PubMed ID: 12808702
[TBL] [Abstract][Full Text] [Related]
11. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
[TBL] [Abstract][Full Text] [Related]
12. The recalcitrant overactive bladder patient.
Ghoniem GM
Geriatrics; 2002 May; 57 Suppl 1():23-9. PubMed ID: 12040600
[No Abstract] [Full Text] [Related]
13. Re: Burgio KL, Goode PS, Richter HE, et al. 2006. Global ratings of patient satisfaction and perceptions of improvement with treatment for urinary incontinence: validation of three global patient ratings. Neurourol Urodynam 25:411-417.
Brown JS
Neurourol Urodyn; 2007; 26(3):456. PubMed ID: 17304526
[No Abstract] [Full Text] [Related]
14. Effect of raloxifene on urinary incontinence: a randomized controlled trial.
Waetjen LE; Brown JS; Modelska K; Blackwell T; Vittinghoff E; Cummings SR;
Obstet Gynecol; 2004 Feb; 103(2):261-6. PubMed ID: 14754693
[TBL] [Abstract][Full Text] [Related]
15. Behavior management improves urinary incontinence in older women living at home.
Rollins G
Rep Med Guidel Outcomes Res; 2002 Mar; 13(5):7-9. PubMed ID: 12440409
[No Abstract] [Full Text] [Related]
16. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
[TBL] [Abstract][Full Text] [Related]
17. Incontinence in older women.
Billington A
Elder Care; 1999 Nov; 11(8):32-3. PubMed ID: 10614306
[No Abstract] [Full Text] [Related]
18. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
Foote J; Glavind K; Kralidis G; Wyndaele JJ
Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
[TBL] [Abstract][Full Text] [Related]
19. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
